Stand up for the facts!
Our only agenda is to publish the truth so you can be an informed participant in democracy.
We need your help.
I would like to contribute
A dose of Wegovy, a GLP-1 drug used for weight loss, is displayed in Front Royal, Va., March 1, 2024. Patients taking GLP-1s should eat a nutrient-dense diet and exercise regularly to prevent damage from malnutrition and dangerously rapid weight loss.(AP)
If Your Time is short
-
Side effects like nausea, vomiting, diarrhea and constipation are common soon after starting GLP-1s or increasing the drug’s dosage.
-
A nutrient-dense diet and regular exercise are essential when on a GLP-1 to prevent long-term damage from malnutrition and rapid weight loss.
-
Weight regain is common after stopping these medications. Doctors recommend working with a physician to plan for next steps if you are interested in stopping the drug.
GLP-1s are everywhere. They’re featured in ads, celebrity headlines, friends’ anecdotes and endless online takes. Yet clarity about what it’s like to actually take these medications is in short supply. Are they a miracle weight-loss drug, or riddled with side effects?
We wanted to better understand what life on GLP-1s for weight loss really looks like: What can you expect when you first start taking the drug? What lifestyle changes do doctors advise? What happens if you stop?
We spoke with three doctors who specialize in weight loss and prescribe these medications. We learned that although the drugs may provide a fast-lane to weight loss, diet and exercise remain key to avoid malnutrition, minimize side effects, and keep your bones and muscles strong.
What are GLP-1s?
GLP-1 stands for glucagon-like peptide-1.
GLP-1 agonists are a whole class of drugs with various generic and brand names — semaglutide (Ozempic/Wegovy/Rybelsus), dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Saxenda/Victoza) and tirzepatide (Mounjaro/Zepbound) to name a few.
Most are injected – sometimes weekly, sometimes daily — but some can be taken as a pill.
U.S. drug regulators first approved GLP-1s in 2005 to treat Type II diabetes. Liraglutide (Saxenda) earned FDA approval in 2014 to treat weight loss, but GLP-1s as a class took off with the 2021 approval of semaglutide (Wegovy) for chronic weight management.
By the fall of 2025, one in eight American adults were taking a GLP-1 drug, a KFF poll found.
These medications regulate blood sugar and reduce appetite, which can lead to significant weight loss. Studies of GLP-1s show patients’ average weight loss ranges from 5% to 20% of their body weight. The drugs also show benefits for other health issues such as sleep apnea, cardiovascular disease and arthritis.

Boxes for the GLP-1 medications Wegovy (semaglutide) and Zepbound (tirzepatide) pictured in California, May 8, 2025. GLP-1s as a class took off when semaglutide was approved for chronic weight management in 2021. (AP)
What to expect when starting a GLP-1
Patients who start GLP-1s for weight loss may first notice they feel more full after eating and think less about food, sometimes called "food noise."
Nausea, vomiting, bloating, diarrhea and constipation are normal in these first few days and after a dosage increase. During this period, patients may find it best to opt out of late-night activities and intense workouts.
Dr. Robert F. Kushner, an obesity medicine specialist and Northwestern University professor emeritus, recommends eating slowly, in smaller portions, and avoiding fatty or greasy foods that may cause bellyaches. And although the drugs reduce hunger, patients on GLP-1s should still eat three meals a day and stay hydrated.
The good news is that the body can get used to the medication. The typical treatment requires starting at a low dose and gradually increasing it every four weeks.
"I think people think, ‘Well, I'm on this low dose, if I feel this bad on the low dose, I'm going to feel terrible on the higher dose,’" said Dr. Daniel Bessesen, chief endocrinologist at the University of Colorado School of Medicine. But patients’ side effects can decrease over time as their dosage stabilizes, he said.
Bessesen said if patients experience bad side effects, lose weight too rapidly or see good progress on a lower dose, they can talk to their doctors about staying on a lower dose longer.
Rare side effects linked to GLP-1 medications include pancreatic inflammation, acute kidney damage and gallbladder issues.

A modified menu catering to the dietary needs of people who use GLP-1 weight loss drugs is displayed at Cuba Libre Restaurant and Rum Bar in Philadelphia, on Friday, March 6, 2026. (AP)
Lifestyle changes to diet and exercise on the medications
So you got on a GLP-1. Now what? Diet and exercise are key.
Dr. Scott Kahan, an obesity medicine specialist in Washington, D.C., said it’s very important that patients continue to get enough calories, even though the medication will make them feel less hungry.
"Losing too much weight or losing too quickly is counterproductive and may be dangerous," he said.
Getting too few calories can lead a person to become deficient in protein, calcium and iron — nutrients the body needs to function.
Losing weight too fast can also harm bone and muscle health. Losing some bone and muscle mass is inevitable any time a person loses significant weight. But losing the weight too rapidly can exacerbate the damage — the body will not only break down fat stores for energy (the goal of weight-loss), but start to break down muscle tissue as well.
To lose weight at a more moderate pace (1-2 pounds a week) and ensure adequate nutrition, here’s what doctors advise.
-
Plan out meals in advance. Think about the week ahead — where’ll you be at mealtimes and what’ll you’ll eat. And don’t skip meals, even if you don’t feel hungry — even a protein bar and yogurt at lunch is better than nothing. Going long periods without eating may lead to worse side effects like nausea.
-
Eat nutritionally dense foods. Because your calorie intake is likely to drop, the ones you do eat should be nutrient-packed. Think fruits and vegetables, lean proteins and whole grains.
-
Get lots of protein and fiber. Sufficient protein intake — at least 1/2 gram per pound of body weight a day — can help protect the body from bone and muscle mass loss. Fiber is also important to keep gastrointestinal side effects like constipation and diarrhea at bay.
-
Exercise to maintain bone and muscle strength. Both cardio and strength and resistance training help mitigate bone and muscle mass loss. Kusher said exercising twice a week is ideal. Certain populations such as seniors and post-menopausal women who are already at risk of bone loss should discuss their bone health with their doctor before taking these medications.
Bessesen said patients should also understand the effect these medications can have on their social life. Holiday meals, happy hours and standing Taco Tuesdays may lead to new conversations. Who do you want to know you are taking the medication? How might you respond to social pressure to eat when you’re not hungry?

Donna Cooper shows her exercise bike at her home in Front Royal, Virginia, on March 1, 2024. Cooper was taking Wegovy when she told The Associated Press that she maintained her fitness regimen with walks with friends. She hoped to continue with a strict diet and exercise plan after she finished taking the drug. (AP)
To stop or not?
Although these medications are often advertised as a short-term strategy, that’s not how doctors see them.
"I tell people they should be prepared to take the medicine long term," Bessesen said, comparing it with a blood pressure or cholesterol medication.
The benefits of these medications appear to last only as long as you are on them. It’s not true for everyone, but people who stop the medication typically regain much of the weight they lost.
It’s not about willpower, but the biologic need to eat Kushner said. People might adhere to certain diet and exercise habits while they are taking the drug, but hunger and food noise returns once they stop. It’s like asking you to "stop breathing, hold your breath for two minutes," Kushner said. "Why can't you? Well, because I can't."
With 20 years of data on using GLP-1s to treat diabetes, scientists haven’t identified any significant long-term complications, Kushner said.
Bessesen said most of his patients want to come off the medication after the weight is lost. Statistics show that most people quit within the first year. Patients who take this route should consult with their doctors about post-GLP-1 weight management strategies.
It may be easy to access GLP-1s online, but doctors don’t recommend going it alone without a doctor’s input. A doctor can help you consider these treatments within the context of your overall health goals and history.
"This is a big deal," Bessesen said.
Our Sources
Interview with Dr. Robert F. Kushner, an obesity medicine specialist and Northwestern University professor emeritus, May 6, 2025
Email interview with Dr. Scott Kahan, an obesity medicine specialist and Director of the National Center for Weight and Wellness, May 7, 2025
Interview with Dr. Daniel Bessesen, chief endocrinologist at the University of Colorado School of Medicine, May 6, 2026
Biomolecules, Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss, March 13, 2025
BMJ, Weight regain after cessation of medication for weight management: systematic review and meta-analysis, Jan. 7, 2026
Bone Research, Weight loss induced bone loss: mechanism of action and clinical implications, Dec. 2, 2025
Cell Reports Medicine, The expanding benefits of GLP-1 medicines, July 15, 2025
Endocrine Practice, Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes, Nov. 27, 2023
GoodRx, 10 GLP-1 Side Effects You Should Know About, Nov. 5, 2025
Harvard Health, GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more, Feb. 5, 2024
Harvard Health, How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond, April 14, 2025
Harvard Health, Trying to lose weight? Be careful not to lose muscle, Jan. 8, 2026
JAMA, Systematic Review Examines GLP-1 Drugs’ Effectiveness and Safety in Patients Without Diabetes, Feb. 7, 2025
Journal of Obesity, A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity, May 10, 2024
KFF, Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford, Nov. 14, 2025
Northwestern, Why do so many people stop taking weight-loss drugs within a year?, Nov. 8, 2024
Orlando Health, Do You Have To Stay on Weight-Loss Drugs Forever? Maybe Not, May 23, 2025
Penn Medicine, Stopping and restarting certain GLP-1s to lose weight may make the drug less effective, April 28, 2026
StatPearls, Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs), Feb. 25, 2024
The Lancet, Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression, March 2026
UCHealth, Many people using GLP-1 weight loss drugs may not be eating enough nutritious food, May 19, 2025
UCLA Health, Rapid weight loss can lead to loss of muscle mass, May 1, 2024
University of Colorado, The Underappreciated Benefits of GLP-1 Receptor Agonists, Nov. 3, 2025
WebMD, Rapid Weight Loss: Is It Safe? Does It Work?, April 23, 2024
Yale Medicine, GLP-1 Agonists: Wonder Drugs of the 21st Century?, July 2, 2024
Drugs, Wegovy (semaglutide) FDA Approval History, April 2, 2026
Food and Drug Administration, FDA approves weight management drug for patients aged 12 and older, Dec. 4, 2020
Food and Drug Administration, FDA Approves First Medication for Obstructive Sleep Apnea, Dec. 20, 2024
American Heart Association Journal, GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes, Dec. 2022
Healthline, GLP-1 Dose Adjustment for Weight Loss, Jan. 12, 2026
Nature, Are obesity drugs causing a severe complication? What the science says, Feb. 20, 2026
JAMA, Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity, Jan. 31, 2025
